Biologic therapy is associated with malignancies among Israeli patients with rheumatoid arthritis: A population-based study.
Ella Katony EizenstatFadi HassanAvivit Golan CohenEugene MerzonIlan GreenZiv PazMohammad E NaffaaPublished in: International journal of rheumatic diseases (2023)
Biologic DMARDs are associated with increased risk of malignancy among Israeli RA patients, presumably contributed by MSC and NMSC. MSC was the most prevalent type of malignancy in this cohort and may indicate a predisposition state among Israeli RA patients.